- Home
- NUWE vs MBIO Comparison
NUWE vs MBIO Comparison
Compare NUWE & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- MBIO
- Stock Information
- Founded
- NUWE 1999
- MBIO 2015
- Country
- NUWE United States
- MBIO United States
- Employees
- NUWE N/A
- MBIO N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- MBIO Health Care
- Exchange
- NUWE Nasdaq
- MBIO Nasdaq
- Market Cap
- NUWE 3.9M
- MBIO 4.7M
- IPO Year
- NUWE N/A
- MBIO N/A
- Fundamental
- Price
- NUWE $9.10
- MBIO $1.47
- Analyst Decision
- NUWE Strong Buy
- MBIO
- Analyst Count
- NUWE 1
- MBIO 0
- Target Price
- NUWE $714.00
- MBIO N/A
- AVG Volume (30 Days)
- NUWE 2.3M
- MBIO 16.2M
- Earning Date
- NUWE 08-12-2025
- MBIO 08-12-2025
- Dividend Yield
- NUWE N/A
- MBIO N/A
- EPS Growth
- NUWE N/A
- MBIO N/A
- EPS
- NUWE N/A
- MBIO N/A
- Revenue
- NUWE $8,787,000.00
- MBIO N/A
- Revenue This Year
- NUWE $6.53
- MBIO N/A
- Revenue Next Year
- NUWE $51.63
- MBIO N/A
- P/E Ratio
- NUWE N/A
- MBIO N/A
- Revenue Growth
- NUWE N/A
- MBIO N/A
- 52 Week Low
- NUWE $6.33
- MBIO $0.89
- 52 Week High
- NUWE $175.98
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- NUWE 37.29
- MBIO 41.50
- Support Level
- NUWE $10.10
- MBIO $1.97
- Resistance Level
- NUWE $16.50
- MBIO $2.09
- Average True Range (ATR)
- NUWE 2.06
- MBIO 0.17
- MACD
- NUWE 0.17
- MBIO -0.13
- Stochastic Oscillator
- NUWE 14.03
- MBIO 4.15
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.